<PAGE>
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------------------
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)
Therapeutic Discovery Corporation
---------------------------------
(Name of Issuer)
Class A Common Stock, Par Value $0.01
-------------------------------------
(Title of Class of Securities)
883376105
---------
CUSIP Number
Peter D. Staple, Esq.
ALZA Corporation
950 Page Mill Road
Palo Alto, California 94303
(650) 494-5000
With a copy to:
Sarah A. O'Dowd, Esq.
Heller, Ehrman, White & McAuliffe
525 University Avenue
Palo Alto, California 94301
(650) 324-7000
------------------------------------------------------
(Name, address and telephone number
of person authorized to receive
notices and communications)
September 29, 1997
----------------------------------------------
(Date of Event which requires
filing of this statement)
<PAGE>
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box: [_]
2
<PAGE>
CUSIP No. 883376105
1) Name of Reporting Persons:
S.S. or I.R.S Identification No. of above person
ALZA Corporation
I.R.S. Identification No. 77-0142070
- --------------------------------------------------------------------------------
2) Check the Appropriate Box if a Member of a Group
(a) [_]
------------------------------------------------------------------
(b) [_]
------------------------------------------------------------------
- --------------------------------------------------------------------------------
3) SEC Use Only
--------------------------------------------------------------
- --------------------------------------------------------------------------------
4) Source of Funds: 00
- --------------------------------------------------------------------------------
5) [_] Check if Disclosure of Legal Proceedings is Required
Pursuant to Items 2(d) or 2(e)
- --------------------------------------------------------------------------------
6) Citizenship or Place of Organization: Delaware
- --------------------------------------------------------------------------------
7) Sole Voting Power
7,734,424 Shares of Class A Common Stock and 100
Shares of Class B Common Stock
-----------------------------------------------------------
Number of Shares 8) Shared Voting Power
Beneficially None
Owned by Each -----------------------------------------------------------
Reporting Person
With 9) Sole Dispositive Power
7,734,424 Shares of Class A Common Stock and 100 Shares
of Class B Common Stock
-----------------------------------------------------------
10) Shared Dispositive Power
None
-----------------------------------------------------------
11) Aggregate Amount Beneficially Owned by Each Reporting Person: 7,734,424
Shares of Class A Common Stock and 100 Shares of Class B Common Stock
- --------------------------------------------------------------------------------
12) [_] Check if the Aggregate Amount in Row (11)
Excludes Certain Shares
- --------------------------------------------------------------------------------
13) Percent of Class Represented by amount in Row (11):
100.0% (See response to Item 3)
- --------------------------------------------------------------------------------
14) Type of Reporting Person
CO
- --------------------------------------------------------------------------------
<PAGE>
Item 1. Security and Issuer.
-------------------
This statement constitutes Amendment No. 2 to the Statement on Schedule
13D, dated June 22, 1993, relating to shares of Class A Common Stock, $.01 par
value per share (the "Class A Common Stock") of Therapeutic Discovery
Corporation, a Delaware corporation ("TDC").
The reporting person, ALZA Corporation, a Delaware corporation, ("ALZA") is
filing this Amendment No. 2 on Schedule 13D because, on September 29, 1997 it
concluded the exercise of its option to purchase all of the issued and
outstanding Class A Common Stock of TDC. As a consequence, ALZA now owns all
issued and outstanding stock of TDC and TDC is a wholly owned subsidiary of
ALZA.
3
<PAGE>
Item 5. Interest in Securities of the Issuer.
------------------------------------
As of September 29, 1997, ALZA owns 7,734,424 shares of Class A Common
Stock and 100 shares of Class B Common Stock of TDC. ALZA owns 100% of the
issued and outstanding stock of TDC.
4
<PAGE>
Item 7. Exhibits.
--------
None.
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
September 30, 1997 ALZA CORPORATION
By: /s/ PETER D. STAPLE
-------------------------------
Peter D. Staple
Senior Vice President and
General Counsel
5
